Recombinant Human NRG1/HRG1 Protein, CF | R&D Systems 5898-NR-050 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human NRG1/HRG1 Protein, CF

catalog :

5898-NR-050

quantity :

50 ug

price :

396 USD

more info or order :

R&D Systems product webpage

citations: 21

Reference
Lemmetyinen T, Viitala E, Wartiovaara L, Kaprio T, Hagstr xf6 m J, Haglund C, et al. Fibroblast-derived EGF ligand neuregulin 1 induces fetal-like reprogramming of the intestinal epithelium without supporting tumorigenic growth. Dis Model Mech. 2023;16: pubmed publisher
Dellaqua T, V xed garo R, Janini L, Dal Canto M, Renzini M, Lodde V, et al. Neuregulin 1 (NRG1) modulates oocyte nuclear maturation during IVM and improves post-IVF embryo development. Theriogenology. 2023;195:209-216 pubmed publisher
Lee M, Lee J, Hsieh J, Lin M, Shih I, You H, et al. Cordycepin inhibits the proliferation of malignant peripheral nerve sheath tumor cells through the p53/Sp1/tubulin pathway. Am J Cancer Res. 2021;11:1247-1266 pubmed
Du Z, Brown B, Kim S, Ferguson D, Pavlick D, Jayakumaran G, et al. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nat Commun. 2021;12:1382 pubmed publisher
Holloway E, Czerwinski M, Tsai Y, Wu J, Wu A, Childs C, et al. Mapping Development of the Human Intestinal Niche at Single-Cell Resolution. Cell Stem Cell. 2021;28:568-580.e4 pubmed publisher
Lee J, Lee J, Song D, Bae H, Doo H, Yu H, et al. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res. 2020;48:130-140 pubmed publisher
Ahmed T, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson S, et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep. 2019;26:65-78.e5 pubmed publisher
Turowec J, Lau E, Wang X, Brown K, Fellouse F, Jawanda K, et al. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. J Biol Chem. 2019;294:1396-1409 pubmed publisher
Osada T, Hartman Z, Wei J, Lei G, Hobeika A, Gwin W, et al. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res. 2018;20:90 pubmed publisher
del Monte Nieto G, Ramialison M, Adam A, Wu B, Aharonov A, D Uva G, et al. Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation. Nature. 2018;557:439-445 pubmed publisher
Schmitt L, Rau A, Seifert O, Honer J, Hutt M, Schmid S, et al. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs. 2017;9:831-843 pubmed publisher
Xu Y, Wang X, Chen Y, Chen S, Yang X, Sun Y, et al. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer. Theranostics. 2017;7:974-986 pubmed publisher
Kawata M, Morikawa S, Shiosaka S, Tamura H. Ablation of neuropsin-neuregulin 1 signaling imbalances ErbB4 inhibitory networks and disrupts hippocampal gamma oscillation. Transl Psychiatry. 2017;7:e1052 pubmed publisher
McElroy S, Castle S, Bernard J, Almohazey D, Hunter C, Bell B, et al. The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis. Am J Pathol. 2014;184:2768-78 pubmed publisher
Desai T, Brownfield D, Krasnow M. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature. 2014;507:190-4 pubmed publisher
Lee C, Lin Y, Bratman S, Feng W, Kuo A, Scheeren F, et al. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res. 2014;74:341-52 pubmed publisher
Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013;93:900-5 pubmed publisher
Gorbatenko A, Olesen C, Mørup N, Thiel G, Kallunki T, Valen E, et al. ErbB2 upregulates the Na+,HCO3(-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4. FASEB J. 2014;28:350-63 pubmed publisher
Ishibashi K, Fukumoto Y, Hasegawa H, Abe K, Kubota S, Aoyama K, et al. Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src. J Cell Sci. 2013;126:625-37 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
Hickinson D, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 2010;16:1159-69 pubmed publisher

product information

brand :

R&D Systems, a Bio-Techne Brand

catalog number base :

5898-NR

SKU :

5898-NR-050

product name :

Recombinant Human NRG1/HRG1 Protein, CF

Description :

The Recombinant Human NRG1/HRG1 Protein, CF from R&D Systems is derived from NS0. The Recombinant Human NRG1/HRG1 Protein, CF has been validated for the following applications: Bioactivity.

target :

Neuregulin-1/NRG1

category :

Proteins and Enzymes

unit size :

50 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

40-43 kDa, reducing conditions

theoretical molecular weight :

24.8 kDa

gene symbol :

NRG1

details of functionality :

Measured in a serum-free cell proliferation assay using MCF-7 human breast cancer cells. Karey, K.P. et al . (1988) Cancer Research 48 :4083. The ED50 for this effect is 20-100 ng/mL.

endotoxin note :

<0.01 EU per 1 µg of the protein by the LAL method.

accessionNumbers :

Q02297

applications :

Bioactivity

source :

NS0-derived Recombinant Human NRG1/HRG1 Protein

USD :

396 USD

alt names :

ARIA, GGF2, GGFglial growth factor, Heregulin-1, HGL, HGLneu differentiation factor, HRG, HRG1, HRG1-alpha, HRG1-beta 1, HRGAneuregulin 1 type IV beta 1a, MST131, MSTP131, NDFheregulin, alpha (45kD, ERBB2 p185-activator), neuregulin 1, neuregulin 1 type IV beta 3, Neuregulin1, NRG1, pro-neuregulin-1, membrane-bound isoform, pro-NRG1, sensory and motor neuron derived factor, SMDF

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage